Long-term results of the use of @entity11440 for the treatment of XXXX .

@entity1 @entity2133 @entity1119 @entity11440 @entity1411
BACKGROUND: Plantar @entity1119 is a common illness with significant impact on quality of life. @entity11440 presents good short-term results, but longer follow-up results are lacking. We evaluated @entity11440 effectiveness in @entity1 who were not surgically treated and who had at least six  months of follow-up. METHODS: From September 2007 to September 2013, 85 consecutive @entity1 were enrolled in our institutional protocol for the "pharmacological-first" treatment of @entity1119 with @entity11440 . Eight @entity1 were lost to follow-up, 15 @entity1 have not yet been under treatment for six  months, and data were available for 39 @entity1 (all female) treated for at least six  months. Data at the start of the protocol, six  weeks after beginning treatment, and at their final visit were analyzed. RESULTS: Twenty-three of the 77 @entity1 (29.87%) did not improve after pharmacological therapy. From the 39 @entity1 with more than six  months of follow-up (median 16.9  months, range 9-71), 79.5% reported moderate/great improvement in @entity1411 after six  weeks of treatment, and this rate increased to 84.7% in the last follow-up visit; 82.85% showed improvement in other sites presenting @entity1119 . @entity2133 was the most common side effect; 51.6% of @entity1 reported it to be moderate/severe at the last visit. CONCLUSION: In @entity1 with good initial response to @entity11440 , more than 82% presented moderate or great improvement in plantar and other sites' excessive sweating; @entity2133 was the most common side effect but was tolerable and did not lead any @entity1 to interrupt treatment.
